PRISM BioLab Co.,LTD
|
| Code |
Sector |
Market |
Lead Underwriter |
Date of listing approval |
IPO Date |
| 206A |
Pharmaceuticals |
Growth |
SMBC Nikko Securities Inc. |
2024/05/27 |
2024/07/02 |
| 【Description】 |
| |
IPO Information |
| Opening Price |
Y489 |
Total Amount |
Y2,070,000,000 |
| IPO Price |
Y450 |
--Company |
Y1,656,000,000 |
Aggregate Value
(based on Initial Price) |
17,288
(Unit:1 million) |
--Leading Shareholder |
Y248,400,000 |
| Listed Shares(total) |
4,600,000 |
--Lead Manager |
Y165,600,000 |
| Trading Unit |
100 |
|
Offering Price PER
(based on previous period) |
-23.57 |
Offering Price PBR
(based on previous period) |
-13.04 |
| 公開価格PER(今期予想ベース) |
-11.26 |
| Initial Price PER |
-25.62 |
Initial Price PBR |
-14.17 |
| New Shares |
4,000,000 |
Existing Shares |
600,000（only O.A.） |
| Shares Outstanding |
Pre IPO |
31,354,800.00 |
PostIPO |
35,354,800.00 |
| Paid Up Capital |
PreIPO |
Y762,246,000 |
PostIPO |
Y1,279,311,300 |
| Use of Funds Raised |
|
Financial Data |
| Units:Y1,000 |
| Fiscal Year End |
|
Revenue |
Current Profit |
Net Profit |
Net Assets |
| 2021/09 |
Consolidated |
- |
- |
- |
- |
| Non-consolidated |
58,801 |
-153,707 |
-155,989 |
1,092,912 |
| 2022/09 |
Consolidated |
- |
- |
- |
- |
| Non-consolidated |
554,396 |
78,666 |
72,962 |
1,674,930 |
| 2023/09 |
Consolidated |
- |
- |
- |
- |
| Non-consolidated |
112,926 |
-497,550 |
-526,914 |
1,148,015 |
Interim Results
2024/03 |
Consolidated |
- |
- |
- |
- |
| Non-consolidated |
115,482 |
-322,855 |
-336,052 |
2,311,962 |
Results Forecast
2024/09 |
Consolidated |
- |
- |
- |
- |
| Non-consolidated |
300,000 |
-914,000 |
-1,160,000 |
- |
| Per Share |
Units:Y1 |
| Fiscal Year End |
|
Dividend |
Net Earning |
Equity |
|
| 2021/09 |
Consolidated |
0.00 |
- |
- |
|
| Non-consolidated |
-7.78 |
-31.16 |
|
| 2022/09 |
Consolidated |
0.00 |
- |
- |
|
| Non-consolidated |
2.67 |
-15.41 |
|
| 2023/09 |
Consolidated |
0.00 |
- |
- |
|
| Non-consolidated |
-19.09 |
-34.50 |
|
| Fiscal Year End |
|
Dividend |
Net Earning |
Equity |
|
Interim Results
2024/03 |
Consolidated |
|
- |
- |
|
| Non-consolidated |
-11.57 |
- |
|
Results Forecast
2024/09
| Consolidated
| 0.00 |
- |
- |
|
| Non-consolidated |
-39.98 |
- |
|
Comment |
| ■Over allotment(600,000） |
| Consolidated Subsidiaries |
| Name |
Address |
| Underwriters |
| Allocation |
Underwriter |
Tel |
| 82% |
SMBC Nikko Securities Inc. |
03-5644-3111 |
| 6% |
Daiwa Securities Co. Ltd |
03-5555-2111 |
| 5% |
Mizuho Securities Co., Ltd |
03-5208-3210 |
| 4% |
SBI SECURITIES Co.,Ltd. |
03-5562-7210 |
| 1% |
IwaiCosmo Securities Co.,Ltd. |
06-6229-2890 |
| 1% |
Matsui Securities Co., Ltd |
03-5216-0606 |
| 1% |
Marusan Securities Co., Ltd |
03-3272-5211 |
| Data |
| Date of incorporation |
2012/04/02 |
| Company address |
Kanagawa 251-8555 |
| Telephone |
0466-53-8383 |
| President |
|
| Homepage |
https://prismbiolab.com/ |
| Auditor |
KPMG AZSA LLC |
|
|
| Major Shareholders |
| Shareholder Name |
Ratio |
| |
16.30% |
| |
12.05% |
| |
11.09% |
| |
8.29% |
| |
6.99% |
| |
6.37% |
| |
5.23% |
| |
3.49% |
| |
3.49% |
| |
2.80% |
| Number of Employees |
22 as of 2024/04/30 |
| Birth Date of Representative |
1963/05/18 |
|
|
IPO最新情報、セミナー・イベント情報などをタイムリーにお届けします。
|
|
IPO関連ニュースをX（旧Twitter）でも掲載中。初値予想アンケートも実施中です！
|
|
今後の躍進が期待される注目銘柄のアナリストレポートをご覧いただけます。
|
|
個人投資家向けIRセミナーを開催しませんか？開催希望企業募集中！
|
|
